Compare SGML & LXRX Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | SGML | LXRX |
|---|---|---|
| Founded | 2011 | 1995 |
| Country | Canada | United States |
| Employees | N/A | N/A |
| Industry | Industrial Machinery/Components | Biotechnology: Pharmaceutical Preparations |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 1.1B | 996.7M |
| IPO Year | 2021 | 2000 |
| Metric | SGML | LXRX |
|---|---|---|
| Price | $5.82 | $1.82 |
| Analyst Decision | Buy | Buy |
| Analyst Count | 4 | 6 |
| Target Price | ★ $10.33 | $4.47 |
| AVG Volume (30 Days) | ★ 2.7M | 1.9M |
| Earning Date | 11-11-2026 | 11-05-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 77.78 |
| EPS | ★ N/A | N/A |
| Revenue | N/A | ★ $49,803,000.00 |
| Revenue This Year | $58.22 | N/A |
| Revenue Next Year | $138.88 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | N/A | ★ 60.24 |
| 52 Week Low | $4.99 | $1.10 |
| 52 Week High | $24.48 | $2.68 |
| Indicator | SGML | LXRX |
|---|---|---|
| Relative Strength Index (RSI) | 32.38 | 62.84 |
| Support Level | N/A | $1.78 |
| Resistance Level | $10.50 | $1.95 |
| Average True Range (ATR) | 0.63 | 0.10 |
| MACD | -0.20 | 0.04 |
| Stochastic Oscillator | 21.95 | 94.74 |
Sigma Lithium Corp together with its direct and indirect subsidiaries, is a commercial producer of lithium concentrate. It holds full interest in four mineral properties: Grota do Cirilo, Sao Jose, Santa Clara, and Genipapo, located in the municipalities of Aracuai and Itinga, in the Vale do Jequitinhonha region in the State of Minas Gerais, Brazil. Geographically, the company operates in Switzerland; United Arab Emirates; Singapore; and Republic of Korea, of which it derives maximum revenue from Switzerland.
Lexicon Pharmaceuticals Inc is a biopharmaceutical company. It is engaged in the discovery, development, and commercialization of pharmaceutical products for the treatment of human diseases. Some of its drug candidates are LX9211, an orally-delivered small molecule drug candidate, and LX9851, an orally-delivered small molecule drug candidate, as a treatment for obesity and associated cardiometabolic.